Heterodimeric Antibody Architecture for Monovalent CD3 and CD38 Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing bispecific antibodies face challenges such as biophysical and pharmacokinetic hurdles, particularly when engaging co-target antigens multivalently, leading to nonspecific activation and potential toxicity, especially in treating hematopoietic malignancies like non-Hodgkin's lymphoma and multiple myeloma.

Innovation Solution

Development of heterodimeric antibodies with engineered Fc domains and variable regions that allow monovalent binding to CD3 and CD38, utilizing amino acid substitutions and domain linkers to form stable heterodimers, reducing nonspecific activation and enhancing therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bispecific antibodies engage co-target antigens multivalently, then binding affinity is improved, but nonspecific activation and toxicity increase

Engineering Contradiction:

Improvebinding affinityVSAvoidnonspecific activation and toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs asymmetric heterodimeric antibody structure where one arm contains a full variable region (VH-VL) for high-affinity binding to the first antigen, while the other arm contains only a scFv (single-chain variable fragment) for lower-affinity binding to the second antigen. This asymmetric design allows differential binding strengths that prevent nonspecific cross-linking while maintaining specific target engagement, thereby reducing toxicity associated with multivalent binding.

Inventive Principle:

Principle #4Asymmetry

2Ease of manufacture

If antibody fragments are used to create bispecifics, then manufacturing and penetration are improved, but stability and half-life deteriorate

Engineering Contradiction:

Improvemanufacturing and penetrationVSAvoidstability and half-life

Core Design Contradiction:

Ease of manufactureVSStability of the object's composition

Solution Approach 1:

The patent merges the advantages of antibody fragments (ease of manufacture, small size) with full-length antibody features (stability, long half-life) by constructing heterodimeric antibodies where one monomer is a complete IgG structure and the other is a modified monomer with scFv-Fc fusion. This hybrid architecture combines the manufacturability and tissue penetration of fragments with the stability and pharmacokinetics of full-length antibodies.

Inventive Principle:

Principle #5Merging (Combining)

3Stability of the object's composition

If full length antibody-like formats are engineered for dual binding, then stability is improved, but bivalent binding to new antigen causes nonspecific activation

Engineering Contradiction:

ImprovestabilityVSAvoidnonspecific activation

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent segments the antigen-binding functions into two distinct types: one arm uses a complete variable region (VH-VL) capable of high-affinity binding, while the other arm uses a scFv with lower affinity. This segmentation of binding functions within the heterodimeric structure allows one arm to provide stable target engagement while the other provides lower-affinity binding that avoids nonspecific cross-linking and activation, thus maintaining stability without causing harmful effects.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS12359002B2Heterodimeric antibodies that bind CD3 and tumor antigens

Publication Date: 2025.07.15 XENCOR INC

AI summary

The present invention is directed to novel heterodimeric antibodies.